Company Indivior PLC

INDV

GB00BN4HT335

Pharmaceuticals

Market Closed - London S.E. Other stock markets 16:35:15 10/09/2024 BST			5-day change	1st Jan Change
739.50 ^GBX	-4.58%		-19.00%	-37.59%

09-05	Transcript : Indivior PLC Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 10:45 AM
09-04	Indivior reports "disappointing" results for study with Aelis Farma	AN

Business description: Indivior PLC

Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.

Number of employees: 1,000

Sales by Activity: Indivior PLC

Fiscal Period: December	2019	2020	2021	2022	2023
Development, Manufacture and Sale of Buprenorphine-Based Prescription Drugs	785M	647M	791M	901M	1.09B

See all business segments

Geographical breakdown of sales: Indivior PLC

Fiscal Period: December	2019	2020	2021	2022	2023
United States	589M	456M	603M	731M	912M
Rest of World (ROW)	196M	182M	181M	164M	176M
United Kingdom	-	9M	7M	6M	5M

See all geographic segments

Managers: Indivior PLC

Director	Title	Age	Since
Mark Crossley CEO	Chief Executive Officer	-	31/12/11
Ryan Preblick DFI	Director of Finance/CFO	-	31/12/11
Cynthia Cetani CMP	Compliance Officer	-	30/09/18
Christian Heidbreder CTO	Chief Tech/Sci/R&D Officer	-	30/11/14
Jason Thompson IRC	Investor Relations Contact	-	-

See INDIVIOR PLC governance

Members of the board: Indivior PLC

Manager	Title	Age	Since
Mark Crossley CEO	Chief Executive Officer	-	31/12/11
Peter Bains BRD	Director/Board Member	66	31/07/19
Graham Hetherington CHM	Chairman	65	31/10/19
Ryan Preblick DFI	Director of Finance/CFO	-	31/12/11
Juliet Thompson BRD	Director/Board Member	57	23/03/21
Joanna Le Couilliard BRD	Director/Board Member	60	23/03/21
Mark Stejbach BRD	Director/Board Member	61	23/03/21
Jerome Lande BRD	Director/Board Member	48	23/03/21
Barbara Ryan BRD	Director/Board Member	64	31/05/22
Keith Humphreys BRD	Director/Board Member	-	11-08

Composition of the Board of Directors

Shareholders: Indivior PLC

Name	Equities	%	Valuation
Two Seas Capital LP 9.981 %	13,260,025	9.981 %	163 M p
Two Seas Capital LP 9.507 %	12,630,026	9.507 %	155 M p
Morgan Stanley & Co. International Plc 7.333 %	9,741,226	7.333 %	120 M p
Oaktree Capital Management LP 7.057 %	9,375,420	7.057 %	115 M p
Société Générale Gestion SA 5.093 %	6,766,479	5.093 %	83 M p

List of INDIVIOR PLC shareholders

Holdings: Indivior PLC

Name	Equities	%	Valuation
AELIS FARMA 5.12%	701,469	5.12%	8,851,599 $

Company details: Indivior PLC

Indivior PLC

10710 Midlothian Turnpike Suite 125

23235, North Chesterfield

+804 379 1090

http://indivior.com

Group companies: Indivior PLC

Name	Category and Sector
RBP Global Holdings Ltd. RBP Global Holdings Ltd. Financial ConglomeratesFinance Part of Indivior PLC, RBP Global Holdings Ltd. is a British investment company. The company is based in Slough, UK. RBP Global Holdings was founded in 2013.	Financial Conglomerates

See all subsidiaries

Specialty & Advanced Pharmaceuticals

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
INDIVIOR PLC	-4.58%	-19.00%	-59.72%	-24.66%	1.27B
MERCK KGAA	+0.24%	-2.10%	+3.43%	-16.48%	81.63B
KYOWA KIRIN CO. LTD.	+0.88%	-1.04%	+23.29%	-20.44%	11.81B
YUHAN CORPORATION	+0.50%	-16.84%	+73.32%	+116.94%	6.77B
SK BIOPHARMACEUTICALS CO., LTD.	-0.38%	-5.88%	+26.98%	-8.37%	6.07B
BETTA PHARMACEUTICALS CO., LTD.	+0.98%	+5.02%	-27.20%	-56.33%	2.19B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	-0.38%	-1.89%	+7.88%	+2.97%	1.96B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.65%	-5.51%	-17.24%	+47.81%	1.88B
SUPERNUS PHARMACEUTICALS, INC.	-1.24%	-3.51%	+9.48%	+25.95%	1.85B
VELOXIS PHARMACEUTICALS A/S	-.--%	-.--%	-	-	1.64B
Average	-0.48%	-4.76%	+4.47%	+7.49%	11.71B
Weighted average by Cap.	+0.07%	-3.04%	+9.36%	-7.42%